Pages that link to "Q53515241"
Jump to navigation
Jump to search
The following pages link to Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible? (Q53515241):
Displaying 6 items.
- Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy (Q24796034) (← links)
- Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group (Q28217407) (← links)
- Health-related quality-of-life assessments in patients with advanced cancer of the prostate (Q35071335) (← links)
- Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. (Q36673526) (← links)
- The effects of tibolone on the human primary glioblastoma multiforme cell culture and the rat C6 glioma model (Q39837267) (← links)
- A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life (Q40579713) (← links)